Key result
Targeting systolic blood pressure to less than 120 mm Hg in patients with chronic kidney disease is hard to substantiate and may lead to polypharmacy, added cost burden, and risk of serious harms.
Why the study?
Although optimizing blood pressure is widely accepted in chronic kidney disease, blood pressure targets in this population are not known, prompting a critical review of the KDIGO 2021 recommendation.
Does targeting systolic blood pressure to less than 120 mm Hg improve outcomes or cause harm in patients with chronic kidney disease compared to standard targets?
Population
Patients with CKD and hypertension
Comparison
Systolic BP target <120 mm Hg vs previous recommendations (<140 mm Hg or <130 mm Hg with proteinuria)
Design
Review
Authors
Loading...
Supports intensive BP control in CKD; extends evidence synthesis to guide practice and future trials.
Does targeting systolic blood pressure to less than 120 mm Hg improve outcomes or cause harm in patients with chronic kidney disease compared to standard targets?
The KDIGO 2021 recommendation for a systolic BP target of <120 mm Hg in CKD patients is challenged due to insufficient robust data and potential for harm.
Jamale et al. (2023) conducted a review in Hypertension in Chronic Kidney Disease. Targeting systolic blood pressure to less than 120 mm Hg vs. <140 mm Hg or <130 mm Hg with proteinuria was evaluated. Targeting systolic blood pressure to less than 120 mm Hg in patients with chronic kidney disease is hard to substantiate and may lead to polypharmacy, added cost burden, and risk of serious harms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: